Blocking a small RNA releases immune signalling in breast cancer models
Experiments link the regulatory RNA miR-30d to two brakes on innate immune signalling in breast cancer cells: maintaining the nuclear envelope and restricting movement of the STING protein. Blocking the RNA increased immune responses and reduced tumour growth in mice. The peer-reviewed study also examined patient-derived organoids and human tumour datasets; its intervention remains preclinical.
Science··Evening
A small RNA restrains the DNA alarm
Breast cancer cells can restrain an innate immune alarm at two separate steps through the regulatory RNA miR-30d. A peer-reviewed study tested this mechanism in cultured cells, patient-derived organoids and mouse tumours, alongside human tumour datasets. The cGAS–STING pathway detects DNA misplaced inside a cell and can trigger an interferon response. Inhibiting miR-30d increased these immune signals, including in three separate patient-derived organoids, miniature tissue models grown outside the body.[1]
Nuclear protection and protein movement act together
One branch of the mechanism preserves the nuclear envelope through proteins including LATS2, YAP and Lamin B1, reducing DNA leakage into the cytoplasm. In parallel, miR-30d restricts movement of STING, a signalling protein, from the endoplasmic reticulum to the Golgi apparatus. Blocking the RNA increased nuclear-envelope abnormalities, DNA leakage and STING trafficking. Experiments that reduced or restored selected proteins tested the links between these processes and the interferon response.[1]
Mouse tumours respond to combined intervention
Tumours grew more slowly and contained more infiltrating immune cells when miR-30d was inhibited in mice with functioning immune systems. Removing STING from tumour cells weakened much of the effect. Combining RNA inhibition with anti-PD-1 immunotherapy further suppressed mouse tumour growth. Human tumour datasets linked higher miR-30d activity with lower immune activation, an observational association. The intervention remains preclinical, with therapeutic safety and effectiveness in patients requiring further investigation.[1]
